| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
This compound does not have a biological target; it is a chemical catalyst. As a strong Lewis acid, it acts as a catalyst by accepting electron pairs from substrates, activating them for reactions. It is used in various organic transformations, including hydrosilylation and polymerization reactions. It is also used as an activator for metallocene catalysts in olefin polymerization.
|
|---|---|
| ln Vitro |
This compound has no biological in vitro activity. Its activity is chemical, functioning as a catalyst. For example, it facilitates the metal-free catalytic reductive cleavage of enol ethers via a proposed mechanism of tandem hydrosilylation and silicon-assisted β-elimination. Its efficiency is measured by reaction conversion and selectivity.
|
| ln Vivo |
This compound is not used in in vivo biological studies. Its applications are in synthetic organic chemistry and materials science. It is used as a catalyst to synthesize complex molecules and polymers. It is not a therapeutic agent.
|
| Enzyme Assay |
Non-cellular assays are not applicable. Its "activity" is assessed in chemical reactions. A typical protocol involves dissolving the substrate in a solvent and adding a catalytic amount of B(C₆F₅)₃. The reaction is then carried out under specific conditions (e.g., inert atmosphere, specific temperature). The progress is monitored and the product is analyzed.
|
| Cell Assay |
This compound is not used in cell-based assays. It is a strong Lewis acid and is moisture-sensitive. It is handled under inert atmosphere and stored in a cool, dark place, often under nitrogen. It is a solid at room temperature (white to gray to brown powder).
|
| Animal Protocol |
In vivo animal experiments do not involve this compound as a test article. It is a chemical reagent for synthesis. If used to synthesize a drug candidate, that candidate would be tested in animals. The borane catalyst itself is not administered.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties are not applicable as this is not a drug. It is a small molecule (MW 511.98) that is a strong Lewis acid. It is sensitive to water and air and must be stored under inert conditions. Its physical state is a solid with a melting point of 126-131°C.
|
| Toxicity/Toxicokinetics |
The toxicity of Tris(perfluorophenyl)borane is not extensively documented, but as a reactive organoborane compound, it should be handled with caution. It may be harmful if swallowed, inhaled, or absorbed through skin. Standard laboratory safety practices, including the use of PPE and working in a fume hood, should be followed. It is not intended for human or veterinary use.
|
| Additional Infomation |
Structure in the first source
Tris(pentafluorophenyl)borane is a versatile Lewis acid catalyst used in organic synthesis and polymer chemistry. Its strong electron-withdrawing groups make it a powerful yet neutral catalyst. It is not a pharmaceutical and has no clinical trials or approved therapeutic status. |
| Molecular Formula |
C18BF15
|
|---|---|
| Molecular Weight |
511.98
|
| Exact Mass |
511.985
|
| CAS # |
1109-15-5
|
| PubChem CID |
582056
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
327.3±42.0 °C at 760 mmHg
|
| Melting Point |
126-131 °C(lit.)
|
| Flash Point |
151.7±27.9 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.455
|
| LogP |
5.91
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
34
|
| Complexity |
566
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
FC1C(=C(C(=C(C=1B(C1C(=C(C(=C(C=1F)F)F)F)F)C1C(=C(C(=C(C=1F)F)F)F)F)F)F)F)F
|
| InChi Key |
OBAJXDYVZBHCGT-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18BF15/c20-4-1(5(21)11(27)16(32)10(4)26)19(2-6(22)12(28)17(33)13(29)7(2)23)3-8(24)14(30)18(34)15(31)9(3)25
|
| Chemical Name |
tris(2,3,4,5,6-pentafluorophenyl)borane
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (195.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (4.88 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.88 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9532 mL | 9.7660 mL | 19.5320 mL | |
| 5 mM | 0.3906 mL | 1.9532 mL | 3.9064 mL | |
| 10 mM | 0.1953 mL | 0.9766 mL | 1.9532 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
